154 related articles for article (PubMed ID: 8840947)
1. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.
Young BA; Marsh CL; Alpers CE; Davis CL
Am J Kidney Dis; 1996 Oct; 28(4):561-71. PubMed ID: 8840947
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
Bren A; Pajek J; Grego K; Buturovic J; Ponikvar R; Lindic J; Knap B; Vizjak A; Ferluga D; Kandus A
Transplant Proc; 2005 May; 37(4):1889-91. PubMed ID: 15919494
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine-associated thrombotic microangiopathy in renal allografts.
Zarifian A; Meleg-Smith S; O'donovan R; Tesi RJ; Batuman V
Kidney Int; 1999 Jun; 55(6):2457-66. PubMed ID: 10354295
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy?
Franz M; Regele H; Schmaldienst S; Stummvoll HK; Hörl WH; Pohanka E
Transplantation; 1998 Nov; 66(9):1258-62. PubMed ID: 9825827
[TBL] [Abstract][Full Text] [Related]
6. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature.
Trimarchi HM; Truong LD; Brennan S; Gonzalez JM; Suki WN
Transplantation; 1999 Feb; 67(4):539-44. PubMed ID: 10071024
[TBL] [Abstract][Full Text] [Related]
7. [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period].
Gutiérrez de la Fuente C; Sola E; Alférez MJ; Navarro A; Cabello M; Burgos D; González Molina M
Nefrologia; 2004; 24 Suppl 3():3-6. PubMed ID: 15219059
[TBL] [Abstract][Full Text] [Related]
8. Rescue treatment for cyclosporine-associated hemolytic-uremic syndrome with intravenous immunoglobulin.
Wen YK; Chen ML
Clin Nephrol; 2006 Jul; 66(1):58-62. PubMed ID: 16878437
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine withdrawal in post-renal transplant thrombotic microangiopathy.
Manzoor K; Ahmed E; Akhtar F; Kazi JI; Naqvi SA; Rizvi SA
Clin Transplant; 2006; 20(1):43-7. PubMed ID: 16556152
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
Fortin MC; Raymond MA; Madore F; Fugère JA; Pâquet M; St-Louis G; Hébert MJ
Am J Transplant; 2004 Jun; 4(6):946-52. PubMed ID: 15147429
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus (FK506) associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in lung transplant salvage with a plasmapheresis and cyclosporin.
Boctor FN
Egypt J Immunol; 2006; 13(2):95-9. PubMed ID: 18689275
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A.
Sarkodee-Adoo C; Sotirescu D; Sensenbrenner L; Rapoport AP; Cottler-Fox M; Tricot G; Ruehle K; Meisenberg B
Transfusion; 2003 Jan; 43(1):78-84. PubMed ID: 12519434
[TBL] [Abstract][Full Text] [Related]
15. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome.
Kaufman DB; Kaplan B; Kanwar YS; Abecassis M; Stuart FP
Transplantation; 1995 Jun; 59(12):1737-9. PubMed ID: 7541579
[No Abstract] [Full Text] [Related]
16. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A.
Zent R; Katz A; Quaggin S; Cattran D; Wade J; Cardella C; Zaltzman J; Fenton S; Cole E
Clin Nephrol; 1997 Mar; 47(3):181-6. PubMed ID: 9105765
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.
Chinnakotla S; Leone JP; Fidler ME; Hammeke MD; Tarantolo S
Transplantation; 2000 Aug; 70(3):550-2. PubMed ID: 10949205
[TBL] [Abstract][Full Text] [Related]
19. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation.
Lee CM; Scandling JD; Krieger NR; Dafoe DC; Alfrey EJ
Transplantation; 1997 Nov; 64(9):1288-94. PubMed ID: 9371670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
